{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:13:55Z","timestamp":1792030435703,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian VIGOUR Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11239-021-02582-5","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T18:02:35Z","timestamp":1635357755000},"page":"841-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes"],"prefix":"10.1007","volume":"53","author":[{"given":"Jay S.","family":"Shavadia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendimagegn","family":"Alemayehu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"deFilippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Westerhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-3445","authenticated-orcid":false,"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"van Diepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"2582_CR1","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1161\/CIRCULATIONAHA.108.784215","volume":"118","author":"RS Velagaleti","year":"2008","unstructured":"Velagaleti RS, Pencina MJ, Murabito JM et al (2008) Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 118:2057\u20132062. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.784215","journal-title":"Circulation"},{"key":"2582_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jacc.2008.08.067","volume":"53","author":"JA Ezekowitz","year":"2009","unstructured":"Ezekowitz JA, Kaul P, Bakal JA et al (2009) Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol 53:13\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2008.08.067","journal-title":"J Am Coll Cardiol"},{"key":"2582_CR3","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","volume":"163","author":"CB Granger","year":"2003","unstructured":"Granger CB, Goldberg RJ, Dabbous O et al (2003) Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163:2345\u20132353. https:\/\/doi.org\/10.1001\/archinte.163.19.2345","journal-title":"Arch Intern Med"},{"key":"2582_CR4","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/01.CIR.102.17.2031","volume":"102","author":"DA Morrow","year":"2000","unstructured":"Morrow DA, Antman EM, Charlesworth A et al (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031\u20132037. https:\/\/doi.org\/10.1161\/01.CIR.102.17.2031","journal-title":"Circulation"},{"key":"2582_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/2048872614542724","volume":"4","author":"DA McAllister","year":"2015","unstructured":"McAllister DA, Halbesma N, Carruthers K et al (2015) GRACE score predicts heart failure admission following acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 4:165\u2013171. https:\/\/doi.org\/10.1177\/2048872614542724","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2582_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.ahj.2008.12.010","volume":"157","author":"QA Truong","year":"2009","unstructured":"Truong QA, Cannon CP, Zakai NA et al (2009) Thrombolysis in myocardial infarction (TIMI) risk index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J 157:673\u2013679. https:\/\/doi.org\/10.1016\/j.ahj.2008.12.010","journal-title":"Am Heart J"},{"key":"2582_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","volume":"113","author":"RS Vasan","year":"2006","unstructured":"Vasan RS (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113:2335\u20132362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.482570","journal-title":"Circulation"},{"key":"2582_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ijcard.2006.04.038","volume":"115","author":"M Grabowski","year":"2007","unstructured":"Grabowski M, Filipiak KJ, Malek LA et al (2007) Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. Int J Cardiol 115:386\u2013390. https:\/\/doi.org\/10.1016\/j.ijcard.2006.04.038","journal-title":"Int J Cardiol"},{"key":"2582_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/2048872616684678","volume":"7","author":"R Klingenberg","year":"2018","unstructured":"Klingenberg R, Aghlmandi S, R\u00e4ber L et al (2018) Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. Eur Heart J Acute Cardiovasc Care 7:129\u2013138. https:\/\/doi.org\/10.1177\/2048872616684678","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2582_CR10","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.ijcard.2013.01.004","volume":"168","author":"S van Diepen","year":"2013","unstructured":"van Diepen S, Newby LK, Lopes RD et al (2013) Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. Int J Cardiol 168:2127\u20132133. https:\/\/doi.org\/10.1016\/j.ijcard.2013.01.004","journal-title":"Int J Cardiol"},{"key":"2582_CR11","doi-asserted-by":"publisher","first-page":"e002586","DOI":"10.1161\/JAHA.115.002586","volume":"5","author":"ML O\u2019Donoghue","year":"2016","unstructured":"O\u2019Donoghue ML, Morrow DA, Cannon CP et al (2016) Multimarker risk stratification in patients with acute myocardial infarction. J Am Heart Assoc 5:e002586. https:\/\/doi.org\/10.1161\/JAHA.115.002586","journal-title":"J Am Heart Assoc"},{"key":"2582_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","volume":"72","author":"J Tromp","year":"2018","unstructured":"Tromp J, Westenbrink BD, Ouwerkerk W et al (2018) Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 72:1081\u20131090. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.050","journal-title":"J Am Coll Cardiol"},{"key":"2582_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ahj.2004.12.015","volume":"149","author":"PW Armstrong","year":"2005","unstructured":"Armstrong PW, Adams PX, Al-Khalidi HR et al (2005) Assessment of pexelizumab in acute myocardial infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 149:402\u2013407. https:\/\/doi.org\/10.1016\/j.ahj.2004.12.015","journal-title":"Am Heart J"},{"key":"2582_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.297.1.43","volume":"297","author":"PW Armstrong","year":"2007","unstructured":"Armstrong PW, Bett N, Brieger D et al (2007) PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297:43\u201351. https:\/\/doi.org\/10.1001\/jama.297.1.43","journal-title":"JAMA"},{"key":"2582_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ahj.2019.09.015","volume":"220","author":"JS Shavadia","year":"2020","unstructured":"Shavadia JS, Granger CB, Alemayehu W et al (2020) High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction. Am Heart J 220:137\u2013144. https:\/\/doi.org\/10.1016\/j.ahj.2019.09.015","journal-title":"Am Heart J"},{"key":"2582_CR16","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G et al (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9:e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192","journal-title":"PLoS ONE"},{"key":"2582_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-94-015-7983-4_14","volume-title":"Survival analysis: state of the art","author":"EW Lee","year":"1992","unstructured":"Lee EW, Wei LJ, Amato DA, Leurgans S (1992) Cox-type regression analysis for large numbers of small groups of correlated failure time observations. Survival analysis: state of the art. Springer, Dordrecht, pp 237\u2013247"},{"key":"2582_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L (2001) Random forests. Mach Learn 45:5\u201332. https:\/\/doi.org\/10.1023\/A:1010933404324","journal-title":"Mach Learn"},{"key":"2582_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","volume":"9","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Verdonschot J, Wang P et al (2021) Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Heart Fail 9:268\u2013277. https:\/\/doi.org\/10.1016\/j.jchf.2020.11.010","journal-title":"JACC Heart Fail"},{"key":"2582_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","volume":"119","author":"SD Prabhu","year":"2016","unstructured":"Prabhu SD, Frangogiannis NG (2016) The biological basis for cardiac repair after myocardial infarction. Circ Res 119:91\u2013112. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303577","journal-title":"Circ Res"},{"key":"2582_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0008-6363(02)00256-0","volume":"54","author":"D Fraccarollo","year":"2002","unstructured":"Fraccarollo D, Galuppo P, Bauersachs J, Ertl G (2002) Collagen accumulation after myocardial infarction: Effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res 54:559\u2013567. https:\/\/doi.org\/10.1016\/S0008-6363(02)00256-0","journal-title":"Cardiovasc Res"},{"key":"2582_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1161\/ATVBAHA.113.302918","volume":"34","author":"X Yin","year":"2014","unstructured":"Yin X, Subramanian S, Hwang SJ et al (2014) Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol 34:939\u2013945. https:\/\/doi.org\/10.1161\/ATVBAHA.113.302918","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2582_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","volume":"51","author":"D Fraccarollo","year":"2008","unstructured":"Fraccarollo D, Galuppo P, Schraut S et al (2008) Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 51:905\u2013914. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.100941","journal-title":"Hypertension"},{"key":"2582_CR24","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1006\/jmcc.1998.0684","volume":"30","author":"M Murakami","year":"1998","unstructured":"Murakami M, Kusachi S, Nakahama M et al (1998) Expression of the \u03b11 and \u03b12 chains of type IV collagen in the infarct zone of rat myocardial infarction. J Mol Cell Cardiol 30:1191\u20131202. https:\/\/doi.org\/10.1006\/jmcc.1998.0684","journal-title":"J Mol Cell Cardiol"},{"key":"2582_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1161\/01.CIR.0000140973.60992.9A","volume":"110","author":"R Querejeta","year":"2004","unstructured":"Querejeta R, L\u00f3pez B, Gonz\u00e1lez A et al (2004) Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110:1263\u20131268. https:\/\/doi.org\/10.1161\/01.CIR.0000140973.60992.9A","journal-title":"Circulation"},{"key":"2582_CR26","doi-asserted-by":"publisher","first-page":"e005565","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","volume":"12","author":"RM Burke","year":"2019","unstructured":"Burke RM, Lighthouse JK, Mickelsen DM, Small EM (2019) Sacubitril\/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Hear Fail 12:e005565. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005565","journal-title":"Circ Hear Fail"},{"key":"2582_CR27","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.jacc.2017.07.734","volume":"70","author":"PE Bartko","year":"2017","unstructured":"Bartko PE, Dal-Bianco JP, Guerrero JL et al (2017) Effect of losartan on mitral valve changes after myocardial infarction. J Am Coll Cardiol 70:1232\u20131244. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.734","journal-title":"J Am Coll Cardiol"},{"key":"2582_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/cells8030264","volume":"8","author":"E Vidak","year":"2019","unstructured":"Vidak E, Javor\u0161ek U, Vizovi\u0161ek M, Turk B (2019) Cysteine cathepsins and their extracellular roles: shaping the microenvironment. Cells 8:264. https:\/\/doi.org\/10.3390\/cells8030264","journal-title":"Cells"},{"key":"2582_CR29","doi-asserted-by":"publisher","first-page":"e008865","DOI":"10.1161\/JAHA.118.008865","volume":"7","author":"TD Nguyen","year":"2018","unstructured":"Nguyen TD, Schwarzer M, Schrepper A et al (2018) Increased protein tyrosine phosphatase 1B (PTP1B) activity and cardiac insulin resistance precede mitochondrial and contractile dysfunction in pressure-overloaded hearts. J Am Heart Assoc 7:e008865. https:\/\/doi.org\/10.1161\/JAHA.118.008865","journal-title":"J Am Heart Assoc"},{"key":"2582_CR30","doi-asserted-by":"publisher","first-page":"e009555","DOI":"10.1161\/JAHA.118.009555","volume":"8","author":"E Bouwens","year":"2019","unstructured":"Bouwens E, Brankovic M, Mouthaan H et al (2019) Temporal patterns of 14 blood biomarker candidates of cardiac remodeling in relation to prognosis of patients with chronic heart failure\u2014the bio-SHiFT study. J Am Heart Assoc 8:e009555. https:\/\/doi.org\/10.1161\/JAHA.118.009555","journal-title":"J Am Heart Assoc"},{"key":"2582_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41569-018-0002-3","volume":"15","author":"CL Liu","year":"2018","unstructured":"Liu CL, Guo J, Zhang X et al (2018) Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials. Nat Rev Cardiol 15:351\u2013370. https:\/\/doi.org\/10.1038\/s41569-018-0002-3","journal-title":"Nat Rev Cardiol"},{"key":"2582_CR32","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","volume":"39","author":"LF Buckley","year":"2018","unstructured":"Buckley LF, Abbate A (2018) Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J 39:2063\u20132069. https:\/\/doi.org\/10.1093\/eurheartj\/ehy128","journal-title":"Eur Heart J"},{"key":"2582_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jacbts.2017.07.006","volume":"2","author":"S Toldo","year":"2017","unstructured":"Toldo S, Van Tassell BW, Abbate A (2017) Interleukin-1 blockade in acute myocardial infarction and heart failure: getting closer and closer. JACC 2:431\u2013433. https:\/\/doi.org\/10.1016\/j.jacbts.2017.07.006","journal-title":"JACC"},{"key":"2582_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijcard.2019.08.007","volume":"297","author":"L Shang","year":"2019","unstructured":"Shang L, Feng M, Zhou X, Tang B (2019) Growth differentiation factor 15: a promising prognostic stratification biomarker in patients with acute coronary syndrome. Int J Cardiol 297:16. https:\/\/doi.org\/10.1016\/j.ijcard.2019.08.007","journal-title":"Int J Cardiol"},{"key":"2582_CR35","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jacc.2019.06.038","volume":"74","author":"A Qamar","year":"2019","unstructured":"Qamar A, Giugliano RP, Bohula EA et al (2019) Biomarkers and clinical cardiovascular outcomes with ezetimibe in the IMPROVE-IT trial. J Am Coll Cardiol 74:1057\u20131068. https:\/\/doi.org\/10.1016\/j.jacc.2019.06.038","journal-title":"J Am Coll Cardiol"},{"key":"2582_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/ATVBAHA.110.213512","volume":"31","author":"MP Bonaca","year":"2011","unstructured":"Bonaca MP, Morrow DA, Braunwald E et al (2011) Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 31:203\u2013210. https:\/\/doi.org\/10.1161\/ATVBAHA.110.213512","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2582_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ejhf.980","volume":"20","author":"M Stenemo","year":"2018","unstructured":"Stenemo M, Nowak C, Byberg L et al (2018) Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail 20:55\u201362. https:\/\/doi.org\/10.1002\/ejhf.980","journal-title":"Eur J Heart Fail"},{"key":"2582_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbadis.2008.01.006","volume":"1782","author":"KJ Gordon","year":"2008","unstructured":"Gordon KJ, Blobe GC (2008) Role of transforming growth factor-\u03b2 superfamily signaling pathways in human disease. Biochim Biophys Acta 1782:197\u2013228. https:\/\/doi.org\/10.1016\/j.bbadis.2008.01.006","journal-title":"Biochim Biophys Acta"},{"key":"2582_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejphar.2015.06.025","volume":"763","author":"WC Meijers","year":"2015","unstructured":"Meijers WC, Van Der Velde AR, Pascual-Figal DA, De Boer RA (2015) Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol 763:115\u2013121. https:\/\/doi.org\/10.1016\/j.ejphar.2015.06.025","journal-title":"Eur J Pharmacol"},{"key":"2582_CR40","doi-asserted-by":"publisher","first-page":"117727191877196","DOI":"10.1177\/1177271918771969","volume":"13","author":"W Mosleh","year":"2018","unstructured":"Mosleh W, Chaudhari MR, Sonkawade S et al (2018) The therapeutic potential of blocking galectin-3 expression in acute myocardial infarction and mitigating inflammation of infarct region: a clinical outcome-based translational study. Biomark Insights 13:1177271918771969. https:\/\/doi.org\/10.1177\/1177271918771969","journal-title":"Biomark Insights"},{"key":"2582_CR41","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.hlc.2016.11.007","volume":"26","author":"UC Sharma","year":"2017","unstructured":"Sharma UC, Mosleh W, Chaudhari MR et al (2017) Myocardial and serum galectin-3 expression dynamics marks post-myocardial infarction cardiac remodelling. Heart Lung Circ 26:736\u2013745. https:\/\/doi.org\/10.1016\/j.hlc.2016.11.007","journal-title":"Heart Lung Circ"},{"key":"2582_CR42","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2011.12.031","volume":"221","author":"A Erkol","year":"2012","unstructured":"Erkol A, Oduncu V, Pala S et al (2012) Plasma osteoprotegerin level on admission is associated with no-reflow phenomenon after primary angioplasty and subsequent left ventricular remodeling in patients with acute ST-segment elevation myocardial infarction. Atherosclerosis 221:254\u2013259. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.12.031","journal-title":"Atherosclerosis"},{"key":"2582_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000339880","volume":"123","author":"S Pedersen","year":"2012","unstructured":"Pedersen S, Mogelvang R, Bjerre M et al (2012) Osteoprotegerin predicts long-term outcome in patients with st-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiol 123:31\u201338. https:\/\/doi.org\/10.1159\/000339880","journal-title":"Cardiol"},{"key":"2582_CR44","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/hrt.2010.206714","volume":"97","author":"G\u00d8 Andersen","year":"2011","unstructured":"Andersen G\u00d8, Knudsen EC, Aukrust P et al (2011) Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 97:460\u2013465. https:\/\/doi.org\/10.1136\/hrt.2010.206714","journal-title":"Heart"},{"key":"2582_CR45","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ijcard.2012.05.101","volume":"167","author":"G Fuernau","year":"2013","unstructured":"Fuernau G, Zaehringer S, Eitel I et al (2013) Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. Int J Cardiol 167:2134\u20132139. https:\/\/doi.org\/10.1016\/j.ijcard.2012.05.101","journal-title":"Int J Cardiol"},{"key":"2582_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCHEARTFAILURE.110.957332","volume":"4","author":"T Ueland","year":"2011","unstructured":"Ueland T, Dahl CP, Kjekshus J et al (2011) Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 4:145\u2013152. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.110.957332","journal-title":"Circ Heart Fail"},{"key":"2582_CR47","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jacc.2019.12.069","volume":"75","author":"JA Chirinos","year":"2020","unstructured":"Chirinos JA, Orlenko A, Zhao L et al (2020) Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 75:1281\u20131295. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.069","journal-title":"J Am Coll Cardiol"},{"key":"2582_CR48","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1136\/heartjnl-2011-301260","volume":"98","author":"R R\u00f8ysland","year":"2012","unstructured":"R\u00f8ysland R, Bonaca MP, Omland T et al (2012) Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart 98:786\u2013791. https:\/\/doi.org\/10.1136\/heartjnl-2011-301260","journal-title":"Heart"},{"key":"2582_CR49","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1161\/01.CIR.0000165119.62099.14","volume":"111","author":"T Ueland","year":"2005","unstructured":"Ueland T, Yndestad A, \u00d8ie E et al (2005) Dysregulated osteoprotegerin\/RANK ligand\/RANK axis in clinical and experimental heart failure. Circulation 111:2461\u20132468. https:\/\/doi.org\/10.1161\/01.CIR.0000165119.62099.14","journal-title":"Circulation"},{"key":"2582_CR50","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","volume":"70","author":"A Bayes-Genis","year":"2017","unstructured":"Bayes-Genis A, N\u00fa\u00f1ez J, Zannad F et al (2017) The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. J Am Coll Cardiol 70:2128\u20132136. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.057","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-021-02582-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T05:06:21Z","timestamp":1653714381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-021-02582-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2582"],"URL":"https:\/\/doi.org\/10.1007\/s11239-021-02582-5","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"3 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. deFilippi received grant support from Roche Diagnostics, Siemens Heathineers and has served as a consultant for Roche Diagnostics, Siemens Heathineers, Ortho Clinical, Abbott Diagnostics, Fiji Rebio, Metanomics, Quidel, UpToDate, and WebMD. Dr. Granger received grant support and consulting fees from Boehringer Ingelheim, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceutica, Pfizer, GlaxoSmithKline, and Sanofi, consulting fees and lecture fees from Boston Scientific, grant support from Merck, and consulting fees from AstraZeneca, Armetheon, Eli Lilly, Gilead, Hoffmann-La Roche, Medtronic, Takeda, and the Medicine Company. Dr. Povsic has received grants from Baxter Healthcare, Caladrius Biosciences, Capricor, CSL Behring, and Janssen Pharmaceuticals; and personal fees from Eli Lilly, NovoNordisk, and Pluristem. Dr. Armstrong has served as a consultant for Bayer and Merck, and received research grants from CSL, Boehringer Ingelheim, Bayer, and Merck. All other authors have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by all enrolling hospital research ethics boards and conforms with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}